******************************************************

This page was prepared by Lynn Kash, RN, Internet Nursing Guide
Pennsylvania Nurses,Emergency Department
http://www.nursefriendly.com/kash/

******************************************************

Leuprolide Acetate(Eligard), Androgen Suppression (Hormone) Therapy, American Cancer Society:"Even though LHRH analogs (also called LHRH agonists) are more expensive and require more frequent doctor visits, most men choose this method over orchiectomy. These drugs lower testosterone levels as effectively as orchiectomy by decreasing the androgens, mainly testosterone, produced by your testicles. LHRH analogs are injected intramuscularly either monthly or every 3, 4, or 12 months by a health professional. The LHRH analogs currently available in the United States include leuprolide (Lupron, Viadur, Eligard), goserelin (Zoladex), and triptorelin (Trelstar)."
http://www.cancer.org/eprise/main/docroot/CRI/content/CRI_2_4_4X_Androgen_Suppression_Hormone_Therapy_36?sitearea=CRI

******************************************************

Leuprolide Acetate(Eligard), General Information, Center Watch:"Eligard 7.5mg (formerly Leuprogel One-Month Depot) has been approved by the FDA for the treatment of advanced prostate cancer. Eligard (for subcutaneous injection) is designed to deliver 7.5 mg of leuprolide acetate at a controlled rate over a one-month therapeutic period. Atrix is developing various leuprolide acetate formulations based on the company's Atrigel drug delivery system. The product is injected into the body in a liquid form, where it solidifies and continuously releases a predetermined dose of leuprolide acetate. Sustained levels of leuprolide, a luteinizing hormone-releasing hormone (LHRH) agonist, decrease testosterone to suppress tumor growth in patients with hormone-responsive prostate cancer."
http://www.centerwatch.com/patient/drugs/dru736.html

******************************************************

Leuprolide Acetate(Eligard), FDA Approves Eligard 22.5mg (Leuprolide Acetate for Injectable Suspension), Three-Month Prostate Cancer Product, July 25, 2002, Doctor's Guide:"Approval of the Eligard 22.5mg (three-month sustained release product), comes following a less than ten-month approval process for the New Drug Application (NDA) and is the second Eligard product to be approved in 2002. Eligard 7.5mg (leuprolide acetate for injectable suspension), a once-a-month sustained release product, was approved in late January 2002 after a ten-month review by FDA. Atrix's marketing partner, Sanofi-Synthelabo Inc. will market both products in the U.S. Eligard 7.5mg was officially launched at the American Urological Association meeting."
http://www.pslgroup.com/dg/2198a2.htm

******************************************************

Leuprolide Acetate(Eligard), Diseases and Conditions, Health News Online:"Today Sanofi-Synthelabo Inc. announced the commercial availability of ELIGARD™ 7.5 mg (leuprolide acetate for injectable suspension), an innovative hormone therapy for the palliative treatment of advanced prostate cancer. ELIGARD 7.5 mg suppresses testosterone to traditional castrate levels and also meets the more stringent guidelines of the National Comprehensive Cancer Network (NCCN). The recently approved one-month formulation employs a unique drug delivery system that delivers leuprolide acetate subcutaneously. The announcement came at the conclusion of the Annual Meeting of the American Urological Association in Orlando.
http://www.healthnewsonline.com/Diseases_and_Conditions/Cancer/Prostate/

******************************************************

Leuprolide Acetate(Eligard), Medical Dictionary, Medical Transcription education Center:"Formerly Leuprogel™. An Atrigel® sustained-release formulation of leuprolide for the treatment of advanced prostate cancer. Eligard is injected subcutaneously as a liquid, solidifies, and slowly releases a predetermined dose of leuprolide continuously as it is bioabsorbed. Eligard 7.5 mg (one-month depot) approved in January 2002; Eligard 22.5 mg (three-month depot) approved in July 2002."
http://mtdesk.com/e.shtml

******************************************************

Leuprolide Acetate(Eligard), New Drup Approval Updates, Mosby's DRUG Consult:"Eligard, formerly Leuprogel One-Month Depot, is injected just under the skin, usually above the hip. Subcutaneously, it becomes a biodegradable implant, with a gradual release of leuprolide acetate, the active ingredient. The 7.5 mg dose is released over a one-month period. In clinical trials, Eligard substantially reduced testosterone levels in men with hormone-responsive prostate cancer, the company said. The company believes Eligard will help repress tumors and make patients feel better."
http://www.mosbysdrugconsult.com/Mosby/PhyGenRx/newapp.html

******************************************************

Leuprolide Acetate(Eligard), Weekly Edition, Oncology News International:"The US Food and Drug Administration (FDA) has approved the 22.5-mg strength of leuprolide acetate for injectable suspension, marketed by Sanofi-Synthelabo as Eligard, for the palliative treatment of advanced prostate cancer. The 7.5-mg, once-monthly, sustained-release form of the drug was approved by the FDA in January of this year. Sustained leuprolide levels lower testosterone levels to suppress growth of tumors in patients with hormone-responsive prostate cancer. The products are injected SC using a small-gauge needle; they then form a solid implant within the body that slowly releases leuprolide as the implant is bioabsorbed."
http://www.cancernetwork.com/news/archive/020725b.htm

******************************************************

Leuprolide Acetate(Eligard), Drug Alerts and News, PDR.net:"The FDA has approved a 22.5mg strength of Atrix Laboratories’ Eligard (leuprolide acetate), a synthetic analog of gonadotropin releasing hormone indicated for the palliative treatment of advanced prostate cancer. Eligard 7.5mg, a once-a-month sustained-release product, was approved in late January 2002. The new formulation is administered SQ every 3 months."
http://www.pdr.net/drug_alerts/nb_DrugAlerts.jsp#12

******************************************************

Leuprolide Acetate(Eligard), June 202 Updates and Alerts, Saunders Nursing Drug Handbook:"Leuprolide has been approved in a 7.5 mg formulation for once monthly subcutaneous injection. The new formulation is designed to deliver 7.5 mg of leuprolide over a one month period. This new formulation is approved for the palliative treatment of advanced prostate cancer. Leuprolide is also available in daily injectable formulations, a 12 month implant and in monthly and 3 or 4 month depot formulations."
http://www.us.elsevierhealth.com/SIMON/SaundersNDH/updates-alerts.html

******************************************************

******************************************************

******************************************************

Nursing Topics, A to Z: A, B, C, D, E, F, G, H, I, K L, M, N, O, P, R, S, T, U, V, W, X, Y, Z